Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit.
Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit.
复制标题
DOI：
10.3390/cancers16020312
复制
发表时间：
2024-01-11
期刊：
影响因子：
5.2
通讯作者：
Wheeler, Deric L.
中科院分区：
文献类型：
--
作者：
Kostecki, Kourtney L.;Iida, Mari;Crossman, Bridget E.;Salgia, Ravi;Harari, Paul M.;Bruce, Justine Y.;Wheeler, Deric L.
头颈癌(HNC)是一种侵袭性癌症，影响全球数十万人，预后相对较差。在过去的十年里，旨在增强患者免疫系统的新疗法已被批准使用，但HNC已经开发出许多不同的方法来帮助患者逃避免疫系统。现有的免疫疗法只针对其中一种机制，允许HNC利用其他机制继续逃避免疫系统。本文详细介绍了HNC用来逃避免疫反应的各种策略，将其分为四大类：逃避、抵抗、抑制和招募。每种免疫逃逸机制都代表了一个潜在的免疫治疗靶点，可用于治疗HNC。头颈部癌(HNC)起源于呼吸道的粘膜衬里，通常与饮酒、吸烟和/或人类乳头瘤病毒(HPV)感染有关。每年新确诊的HNC病例超过60万例，使其成为全球第六大最常见的癌症。从历史上看，治疗包括手术、放射和化疗，虽然这些治疗仍然是当前治疗的支柱，但最近几种免疫疗法已被食品和药物管理局(FDA)批准用于HNC。自20世纪初以来，人们一直在探索免疫系统在肿瘤发生和癌症进展中的作用，最终形成了目前癌症免疫编辑的三阶段模型。在消除、平衡和逃逸三个阶段中的每一个阶段，癌细胞都会发展并利用多种策略来达到或保持在最后阶段逃逸，此时肿瘤能够生长和转移，几乎没有来自免疫系统的有害干扰。在本文中，我们总结了HNC逃避免疫系统的许多策略，包括逃避免疫检测、抵抗免疫细胞攻击、抑制免疫细胞功能和招募亲肿瘤免疫细胞。
Head and neck cancer (HNC) is an aggressive form of cancer that affects hundreds of thousands of people worldwide and has a relatively poor prognosis. In the last decade, new therapeutics designed to enhance a patient’s immune system have been approved for use, but HNC has developed many different methods that help it escape the immune system. The existing immunotherapies target only one of these mechanisms, allowing HNC to utilize others to continue to elude the immune system. This review details the various strategies used by HNC to escape the immune response, dividing them into four general categories: evade, resist, inhibit, and recruit. Each of the immune escape mechanisms represents a potential immunotherapy target that could be used to treat HNC. Head and neck cancers (HNCs) arise from the mucosal lining of the aerodigestive tract and are often associated with alcohol use, tobacco use, and/or human papillomavirus (HPV) infection. Over 600,000 new cases of HNC are diagnosed each year, making it the sixth most common cancer worldwide. Historically, treatments have included surgery, radiation, and chemotherapy, and while these treatments are still the backbone of current therapy, several immunotherapies have recently been approved by the Food and Drug Administration (FDA) for use in HNC. The role of the immune system in tumorigenesis and cancer progression has been explored since the early 20th century, eventually coalescing into the current three-phase model of cancer immunoediting. During each of the three phases—elimination, equilibrium, and escape—cancer cells develop and utilize multiple strategies to either reach or remain in the final phase, escape, at which point the tumor is able to grow and metastasize with little to no detrimental interference from the immune system. In this review, we summarize the many strategies used by HNC to escape the immune system, which include ways to evade immune detection, resist immune cell attacks, inhibit immune cell functions, and recruit pro-tumor immune cells.
登录
查看更多内容
DOI：
10.1084/jem.194.4.541
发表时间：
2001-08-20
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Blazar BR;Lindberg FP;Ingulli E;Panoskaltsis-Mortari A;Oldenborg PA;Iizuka K;Yokoyama WM;Taylor PA
通讯作者：
Taylor PA
影响因子：
8.8
作者：
Banerjee H;Nieves-Rosado H;Kulkarni A;Murter B;McGrath KV;Chandran UR;Chang A;Szymczak-Workman AL;Vujanovic L;Delgoffe GM;Ferris RL;Kane LP
通讯作者：
Kane LP
影响因子：
19
作者：
Ackerman, Daniel;Simon, M. Celeste
通讯作者：
Simon, M. Celeste
影响因子：
4.1
作者：
Bie T;Zhang X
通讯作者：
Zhang X
DOI：
10.1111/ajt.14645
发表时间：
2018-05
期刊：
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
影响因子：
--
作者：
Braza MS;Conde P;Garcia M;Cortegano I;Brahmachary M;Pothula V;Fay F;Boros P;Werner SA;Ginhoux F;Mulder WJM;Ochando J
通讯作者：
Ochando J